Al-Dossari Ranna, Kalra Monica, Adkison Julie, Nguyen Bich-May
From the Memorial Family Medicine Residency, Sugar Land, TX (RAD); Memorial Family Medicine Residency, Sugar Land, TX (MK); Memorial Family Medicine Residency, Sugar Land, TX (JA); Department of Health Systems and Population Health Sciences, University of Houston Tilman J. Fertitta Family College of Medicine, Houston, TX (BMN).
J Am Board Fam Med. 2024 Sep-Oct;37(5):909-918. doi: 10.3122/jabfm.2023.230471R1.
Urinary incontinence management varies depending on the type of incontinence and severity of symptoms. Types of incontinence include stress (SUI), urge or overactive bladder (OAB), mixed, neurogenic, and overflow incontinence. First-line treatment for OAB and SUI is nonpharmacologic management. Behavioral therapy is first-line treatment for urge incontinence. Vaginal mechanical devices (cones, pessaries, and urethral plugs), pelvic floor muscle training, and electroacupuncture are recommended as first-line treatment for women with SUI. Biofeedback and electric muscle stimulation can be adjunctive therapy for SUI. Antimuscarinics and β-3 agonists can be used as adjective therapy for those with OAB who do not improve with behavioral therapy. β-3 agonists have less anticholinergic side effects compared with antimuscarinics for OAB. Adverse medication effects can often lead to discontinuation due to poor tolerability. Third-line therapies are for those who fail conservative and pharmacologic therapies and lack high-grade evidence. Neuromodulation, neurotoxin injections, vaginal laser therapy, and acupuncture are third-line in OAB management. Pharmacologic management with α-1-blockers is recommended as first-line treatment for moderate to severe overflow incontinence from BPH. 5-α reductase inhibitors can be used as an adjunct medication in those with refractory overflow incontinence symptoms and a PSA ≥ 1.5 mg/dL. Clean intermittent catheterization is first-line therapy for neurogenic bladder but can increase risk of catheter-associated urinary tract infection. Clinicians should assess type of incontinence, patient goals, side effect profile, and tolerability to determine an individualized treatment plan for each patient.
尿失禁的管理因失禁类型和症状严重程度而异。失禁类型包括压力性(SUI)、急迫性或膀胱过度活动症(OAB)、混合性、神经源性和充溢性尿失禁。OAB和SUI的一线治疗是非药物管理。行为疗法是急迫性尿失禁的一线治疗方法。阴道机械装置(球囊、子宫托和尿道塞)、盆底肌肉训练和电针疗法被推荐为SUI女性的一线治疗方法。生物反馈和电肌肉刺激可作为SUI的辅助治疗。抗毒蕈碱药物和β-3激动剂可用于对行为疗法无改善的OAB患者的辅助治疗。与用于OAB的抗毒蕈碱药物相比,β-3激动剂的抗胆碱能副作用更少。药物不良反应通常因耐受性差而导致停药。三线治疗适用于保守治疗和药物治疗失败且缺乏高级别证据的患者。神经调节、神经毒素注射、阴道激光治疗和针灸是OAB管理中的三线治疗方法。α-1阻滞剂的药物管理被推荐为BPH所致中度至重度充溢性尿失禁的一线治疗方法。5-α还原酶抑制剂可用于难治性充溢性尿失禁症状且PSA≥1.5mg/dL的患者作为辅助药物。清洁间歇性导尿是神经源性膀胱的一线治疗方法,但会增加导管相关尿路感染的风险。临床医生应评估失禁类型、患者目标、副作用情况和耐受性,以确定每位患者的个体化治疗方案。